ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Non-Hodgkin lymfomen (NHL) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Burkitt lymfoom' van de HOVON Lymfoom werkgroep. 

Klik HIER voor de richtlijn 'Diffuus grootcellig B-cel lymfoom' van de HOVON Lymfoom werkgroep.

Klik HIER voor de richtlijn 'Folliculair lymfoom' van de HOVON Lymfoom werkgroep.

Klik HIER voor de richtlijn 'Mantelcellymfoom' van de HOVON Lymfoom werkgroep.

Klik HIER voor de richtlijn 'Marginale zone lymfoom' van de HOVON Lymfoom werkgroep.

Klik HIER voor de richtlijn 'Primair zenuwstelsel lymfoom' van de HOVON Lymfoom werkgroep. 

Literatuur algemeen

  1. Cheson et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. JCO. 2014;32(27)3059-3068
  2. Barrington et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.JCO. 2014;32(27):3048-3058
  3. Cheson BD et al. International Harmonization Project on Lymphoma. J Clin Oncol 2007; 25: 579-86

Literatuur BL

  1. Jacobson et al. How I treat Burkitt lymphoma in adults. Blood. 2014;124(19):2913-2920

Literatuur DLBCL  

  1. Fend F et al. How we diagnose and treat vitreoretinal lymphoma. BJH 2016;173(5):680-692
  2. Oudshoorn MA et al. Systemische intensieve immuno-chemotherapie, zonder lokale behandeling, bij oudere patiënten met een centraalzenuwstelsellokalisatie van een agressief B-cellymfoom. NTVH 2017;14:15-20
  3. Soussain C et al. Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008;28:2512-2518
  4. Vitolo U et al. First-line treatment of primary testicular diffuse large B-cell lymphome with rituximab-CHOP, CNS profylaxis and contralaterale testis irradiation: final results of an international phase II trial. JCO 2011;29(20):2766-2772
  5. Giulino-Roth L et al. Outcome of adults and children with primary mediastinal B-cell lymphoma treated with dose –adjusted EPOCH-R. BJH 2017;179:739-747
  6. Dunleavy K et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. NEJM 2013;368(15):1408-1416
  7. Martelli M et al. primary medistinal Large B-cell lymphoma. Critical reviews in oncology/hematology 2017;113:318-327
  8. Peyrade F et al. Attenuate immunochemotherapy regimen (R=miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lanc oncol 2011;12:460-468
  9. Jahnke K, et al. Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmology. 2007;1(3):247-258
  10. Melani C. et al. End of treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: A paradigm shift in clinical decision making. Heamatologica. 2018; epub
  11. Sehn L.H. et al. Added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-cell lymphoma patients: results from the international phase III GOYA study. Clinically. ASH 2018 abstract 283
  12. Poeschel V. et al. Excellent outcome of young patients (18-60 years) with favourable-prognosis diffuse large B-cell lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of rituximab: results of the 592 patients of the Flyer trial of the Dshnhl/GLA. Clinically. ASH 2018 abstract 781
  13. Vitolo U et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis and contralateral testis irradiation: final results of an international phase II trial. J. Clin. Oncol 2011; 29:2766-2772
  14. Ferreri, AJ et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era, Br J Haematol 2015; 168:654-662
  15. Holte, H et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 2013; 24:1385-1392
  16. McKay, P et al. The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper. Br J Haematol 2020; 190:708-714
  17. Wilson, MR et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. Blood 2020; Adv 4:3586-3593
  18. Pettengel R et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol 2012; 13:696-706
  19. Lopéz A et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory / relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 2008; 80:127-132
  20. Corazzelli G et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009; 64:907–916
  21. Mounier N et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory / relapsed diffuse large B-cell lymphoma who are not 42 candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica 2013; 98:1726-1731
  22. Czuczman MS et al. A phase 2/3 multicenter, randomized, openlabel study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res 2017; 23:4127-4137

Literatuur FL

  1.  Solal-Céligny P et al. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1;104(5):1258-65
  2. Buske C et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006 Sep 1;108(5):1504-8
  3. Marcus R et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008 Oct 1;26(28):4579-86
  4. Ardeshna KM et al. British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003 Aug 16;362(9383):516-22
  5. Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014 Apr;15(4):424-35
  6. Brice P et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997 Mar;15(3):1110-7
  7. Kahl BS et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014 Oct 1;32(28):3096-102
  8. Young RC et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6
  9. Hiddemann W et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005 Dec 1;106(12):3725-32
  10. Federico M et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Apr 20;31(12):1506-13
  11. Rummel MJ et al. Study group indolent Lymphomas (StiL).Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10
  12. Flinn IW et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52
  13. Hoskin et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet oncol.2014;15(4):457-63
  14. Lowry et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiothe Oncol. 2011;100(1):86-92
  15. Flinn et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123(19):2944-2952

Literatuur MZL

  1. Dreyling M, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann of Onco 2013;24:857-877
  2. Arcaine et al. Integruppo Italiano Lindomi. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107(12):4643-4649
  3. Montalban et al. Splenic marginal zone lymphoma study group risk stratification for splenic marginal zone lymphoma based on haemoglobine concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadeonpathy development and validation on 593 cases. Br J Haem 2012; 159(2):164-171
  4. Kalpadakis et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist. 2013;18(2):190–197
  5. Bennett et al. Rituximab monotherapy in splenic marginal zone lymphoma instead of splenectomy. Br J Haematol. 2010;149(Suppl. 1):45
  6. Hieblemont C. et al. A MALT lymphoma prognostic index. Blood 2017; 130(12):1409-1417
  7. Walewska R. et al. Guideline for the diagnosis and management of marginal zone lymphomas: a British society of haematology guideline. Br J Haematol. 2024; 204:86-107

Literatuur MCL

  1. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-10
  2. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520-31
  3. Le Gouill et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. NEJM. 2017;377(13):1250-1260
  4. Robinson S, Dreger P, Caballero D, et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia. 2015;29(2):464-73
  5. Cohen JB, Han X, Jemal A, et al. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer. 2016
  6. Cheah CY, Seymour JF, Wang ML. Mantle Cell Lymphoma. J Clin Oncol. 2016;34(11):1256-69.
  7. Vaughn JE, Sorror ML, Storer BE, et al. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer. 2015;121(20):3709-16
  8. Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770-8
  9. Trneny M, Lamy T, Walewski J, et al. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17(3):319-31
  10. O'Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol. 2009;145(1):34-9
  11. Website: http://bloodref.com/lymphoid/lymphoma/mipi
  12. Dreyling M, et al. Newly Diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines. Ann Oncol 2017;28(suppl 4):iv62-71

Literatuur nasaal NK/T-cel lymfoom

  1. Doesum J.A. van, Huls G.A., Diepstra A., Beijert M., Meerten T. van, Nijland M. Extranodaal NK/T-cellymfoom nasaal type: diagnostiek en behandeling. Ned Tijdschr Hematol 2019;16:382-9

Literatuur perifeer T-cel lymfoom

  1. Moskowitz AJ, et al. How I treat the peripheral T-cell lymphomas. Blood. 2014;123(17):2636-2644
  2. Suzuki R. NK/T Cell Lymphoma: Updates in Therapy. Curr Hematol Malig Rep. 2018 Jan 24
  3. Horwitz S, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double blind, randomised, phase 3 trial. Lancet 2019; 393: 229-40

 

Ga terug naar de NHL homepage of lees meer over NHL:

Ga terug naar de algemene homepage Behandelprotocollen.